Product
Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
1 clinical trial
3 indications
Indication
GlioblastomaIndication
GliomaIndication
Malignant GliomaClinical trial
Dose-finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant Against Recurrent WHO Grade IV Malignant GliomaStatus: Completed, Estimated PCD: 2017-06-27